Let's break down Anuh Pharma (ANUHPHARMA) — from its financial performance to how the market is valuing the stock.
Anuh Pharma Revenue Trend
For FY2025, Anuh Pharma recorded revenue of ₹662 Cr. That's 2.2% higher than the ₹647 Cr it brought in during FY2024.
Stepping back, the 10-year revenue CAGR of 8.8% shows Anuh Pharma has been growing at a moderate, sustainable pace.
In terms of scale, Anuh Pharma's ₹662 Cr in annual revenue positions it as a smaller pharmaceuticals company.
It's been 5 years of continuous revenue growth for Anuh Pharma — a pattern worth noting.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹662 Cr | +2.2% |
| FY2024 | ₹647 Cr | +22.7% |
| FY2023 | ₹527 Cr | +8.4% |
| FY2022 | ₹487 Cr | +12.7% |
| FY2021 | ₹432 Cr | — |
View Anuh Pharma's full 10-year revenue trend with CAGR analysis →
Anuh Pharma Profitability
On the earnings front, Anuh Pharma posted ₹47.4 Cr for FY2025 — a 21.2% drop from ₹60.1 Cr in FY2024.
Profitability per rupee of revenue dipped, with net margin at 7.2% against 9.3% in FY2024.
Diluted EPS came in at ₹4.73 for FY2025, down from ₹5.99 a year earlier.
Is Anuh Pharma Undervalued
Running the numbers through the P/E Ratio model gives a fair value of ₹83 for Anuh Pharma.
Anuh Pharma shares are currently trading at ₹76.53.
Craytheon also calculates intrinsic value using the EPS Growth and DCF models. The full breakdown with assumptions is available in the detailed analysis.
| Model | Est. Fair Value | vs. Current Price |
|---|---|---|
| P/E Ratio | ₹83 | 8.3% upside to fair value |
| EPS Growth | Upgrade | Upgrade |
| DCF | Upgrade | Upgrade |
See all valuation models for Anuh Pharma with detailed assumptions →
Anuh Pharma Balance Sheet
Proportional view as of 3 Jun 2026. Hover blocks for details.
Assets
Liabilities & Equity
Total assets stood at ₹5.07B at the end of FY2025, up 13.7% from ₹4.46B a year earlier.
Receivables is the largest block at 42.6%, followed by Inventories at 14.7% and Cash & ST Investments at 14.5%.
Equity makes up 64.4% of liabilities and equity, with debt at 2.1% and operating liabilities at 33.5%. Over the year, debt is up 304.3% and equity is up 12.0%.
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 734.15M |
| Receivables | 2.16B |
| Inventories | 744.81M |
| Property, Plant & Equipment | 498.49M |
| Investments | 519.55M |
| Intangibles & Goodwill | 1.21M |
| Other Assets | 409.40M |
| Category | Value |
|---|---|
| Equity | 3.26B |
| Short-term Debt | 108.28M |
| Long-term Debt | 583,000 |
| Trade Payables | 1.57B |
| Other Liabilities | 128.72M |
Anuh Pharma — The Bottom Line
Bringing the key threads together for Anuh Pharma (ANUHPHARMA) as a pharmaceuticals investment opportunity.
Revenue of ₹662 Cr in FY2025, up 2.2% year-over-year.
Long-term revenue has been compounding at 8.8% annually over 10 years.
The company is profitable, with a net margin of 7.2% and net income of ₹47.4 Cr.
The P/E Ratio model implies 8.3% upside to fair value from the current price. The remaining two models are worth cross-checking before drawing a conclusion — sign up to see the full analysis.
Unlock Full Analysis
There's more to the story. Craytheon's full profile for Anuh Pharma includes three valuation models, decade-long financials, and insider activity.